| Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the … Journal of Clinical Oncology 35 (6), 605-612, 2017 | 410* | 2017 |
| A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017 | 330 | 2017 |
| GIMEMA AML1310 TRIAL OF RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA Blood, 2019 | 185* | 2019 |
| Extramedullary Involvement at Relapse in Acute Promyelocytic Leukemia Patients Treated or Not With All-Trans Retinoic Acid: A Report by the Gruppo Italiano … G Specchia, F Lo Coco, M Vignetti, G Avvisati, P Fazi, F Albano, ... Journal of Clinical Oncology 19 (20), 4023-4028, 2001 | 167 | 2001 |
| The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview M Baccarani, F Castagnetti, G Gugliotta, G Rosti, S Soverini, A Albeer, ... Leukemia 33 (5), 1173-1183, 2019 | 124 | 2019 |
| The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib on behalf of the GIMEMA CML Working Party American journal of hematology, 2017 | 108 | 2017 |
| Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib F Castagnetti, G Gugliotta, M Breccia, F Stagno, A Iurlo, F Albano, ... Leukemia 29 (9), 1823-1831, 2015 | 107 | 2015 |
| Differences among young adults, adults and elderly chronic myeloid leukemia patients F Castagnetti, G Gugliotta, M Baccarani, M Breccia, G Specchia, L Levato, ... Annals of Oncology 26 (1), 185-92, 2015 | 105 | 2015 |
| The biological characteristics of CD34+ CD2+ adult acute promyelocytic leukemia and the CD34 CD2 hypergranular (M3) and microgranular (M3v) phenotypes F Albano, A Mestice, A Pannunzio, F Lanza, B Martino, D Pastore, ... haematologica 91 (3), 311-316, 2006 | 104 | 2006 |
| Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic … N Testoni, G Marzocchi, S Luatti, M Amabile, C Baldazzi, M Stacchini, ... Blood, The Journal of the American Society of Hematology 114 (24), 4939-4943, 2009 | 101 | 2009 |
| Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA … F Castagnetti, N Testoni, S Luatti, G Marzocchi, M Mancini, S Kerim, ... Journal of clinical oncology 28 (16), 2748-2754, 2010 | 99 | 2010 |
| A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia B Rocca, A Tosetto, S Betti, D Soldati, G Petrucci, E Rossi, A Timillero, ... Blood, The Journal of the American Society of Hematology 136 (2), 171-182, 2020 | 96 | 2020 |
| PML-RARα kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukemia treated with ATRA and ATO or ATRA and chemotherapy LCF Cicconi L, Divona M, Ciardi C, Ottone T, Ferrantini A, Lavorgna S ... Leukemia, 2016 | 94 | 2016 |
| Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study S Soverini, L Bavaro, C De Benedittis, M Martelli, A Iurlo, N Orofino, ... Blood, The Journal of the American Society of Hematology 135 (8), 534-541, 2020 | 91 | 2020 |
| Next-Generation Sequencing in Acute Lymphoblastic Leukemia N Coccaro, L Anelli, A Zagaria, S Giorgina, F Albano International Journal of Molecular Sciences 20 (12), 2929, 2019 | 90 | 2019 |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP M Baccarani, E Abruzzese, V Accurso, F Albano, M Annunziata, S Barulli, ... Blood advances 3 (24), 4280-4290, 2019 | 83 | 2019 |
| Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial L Cicconi, U Platzbecker, G Avvisati, F Paoloni, C Thiede, M Vignetti, ... Leukemia 34 (3), 914-918, 2020 | 70 | 2020 |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE … Hematological Oncology, 2019 | 66 | 2019 |
| Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients. MG Soverini S, De Benedittis C, Machova Polakova KM, Linhartova J ... Oncotarget, 2016 | 64 | 2016 |
| TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing GSFA Crescenzio Francesco Minervini, Cosimo Cumbo, Paola Orsini, Claudia ... Diagnostic Pathology 11 (96), 2016 | 63* | 2016 |
francesco lo cocoProfessore Ordinario di Malattie del Sangue, Università Tor Vergata, Roma在 uniroma2.it 的电子邮件经过验证
